- Home
- RDHL vs GLTO Comparison
RDHL vs GLTO Comparison
Compare RDHL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- GLTO
- Stock Information
- Founded
- RDHL 2009
- GLTO 2011
- Country
- RDHL Israel
- GLTO Denmark
- Employees
- RDHL N/A
- GLTO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- GLTO Health Care
- Exchange
- RDHL Nasdaq
- GLTO Nasdaq
- Market Cap
- RDHL 4.3M
- GLTO 4.5M
- IPO Year
- RDHL N/A
- GLTO 2020
- Fundamental
- Price
- RDHL $2.10
- GLTO $3.45
- Analyst Decision
- RDHL
- GLTO Buy
- Analyst Count
- RDHL 0
- GLTO 1
- Target Price
- RDHL N/A
- GLTO $10.00
- AVG Volume (30 Days)
- RDHL 18.8K
- GLTO 14.9K
- Earning Date
- RDHL 08-28-2025
- GLTO 08-11-2025
- Dividend Yield
- RDHL N/A
- GLTO N/A
- EPS Growth
- RDHL N/A
- GLTO N/A
- EPS
- RDHL N/A
- GLTO N/A
- Revenue
- RDHL $8,042,999.00
- GLTO N/A
- Revenue This Year
- RDHL $381.91
- GLTO N/A
- Revenue Next Year
- RDHL N/A
- GLTO N/A
- P/E Ratio
- RDHL N/A
- GLTO N/A
- Revenue Growth
- RDHL 23.17
- GLTO N/A
- 52 Week Low
- RDHL $1.71
- GLTO $2.01
- 52 Week High
- RDHL $20.28
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- RDHL 61.27
- GLTO 56.21
- Support Level
- RDHL $2.00
- GLTO $3.24
- Resistance Level
- RDHL $2.08
- GLTO $3.60
- Average True Range (ATR)
- RDHL 0.09
- GLTO 0.23
- MACD
- RDHL 0.03
- GLTO -0.02
- Stochastic Oscillator
- RDHL 100.00
- GLTO 65.64
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.